Objectives: The molecular basis and mechanisms of Juvenile Nasopharyngeal Angiofibromas (JNA) pathogenesis are still unknown. Despite being a rare and benign neoplasm, JNA is a locally aggressive and potentially destructive neoplasm among head and neck tumors, typically diagnosed in young males. The advancement of genome technologies and analytical tools has provided an unparalleled opportunity to explore the intricacy of JNA. The present study provides the first evidence of the involvement of chromosome Y genes in JNA. Methods: Thirteen JNA patients at an advanced disease stage and 5 age-matched male controls were registered for this study. Whole-exome sequencing (WES) analysis was conducted followed by functional analysis to understand the molecular mechanism of the JNA. Results: WES analysis revealed a high prevalence of mutations in 14 genes within the protein-coding, Male-Specific Region of the Y-chromosome of young males (mean age: 13.8) with JNA. These mutations, occurring at 28 distinct positions, were characterized as moderate to high impact and were prevalent in 9 JNA patients but not in the control group. The most frequently mutated genes were USP9Y and UTY, followed by KDM5D, DDX3Y and TSPY4. The expression of USP9Y, UTY and DDX3Y was found to be co-modulated, implying their coordinated regulation as a complex. Furthermore, somatic mutations were detected in genes previously linked to JNA. Conclusion: The wide array of genetic and somatic mutations identified in JNA provides novel insight into JNA pathophysiology.

The authors have declared no competing interest.

This work is supported by the AIIMS Interdisciplinary Collaborative Intramural Research Project AC-31 (Dr. Bhupendra Verma and Dr. Hitesh Verma).

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Institute Ethics Committee of All India Institute of Medical Sciences (AIIMS), New Delhi, India, gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors